Revenue Growth and High-End Guidance
Butterfly Network reported third quarter 2025 results at the higher end of revenue guidance with a 5% growth over the prior year, primarily driven by higher average selling prices and increased volume in the U.S.
AI Strategy and Milestones
Butterfly's AI strategy accelerated in Q3 with the POCUS CARE trial highlighting real-world impact, improving clinical management in 35% of cases, reducing hospital length of stay by 30%, and generating over $750,000 in cost savings.
Launch of New Products and Certifications
The launch of HeartFocus and ISO 27001 certifications strengthened Butterfly's position as a trusted partner, enhancing enterprise readiness and expanding global reach.
Development of Next-Gen Chip Technology
Completion of the P5.1 chip development with MEMS capabilities and ongoing development of Apollo AI chip expected to enhance ultrasound processing and AI capabilities.